China Meheco Group 
Welcome,         Profile    Billing    Logout  
  Products    Diseases    Products    Trials    News 


«12...4567891011121314...215216»
  • ||||||||||  Paxlovid (nirmatrelvir/ritonavir) / Pfizer
    Retrospective data, Journal:  Pediatric Nirmatrelvir/Ritonavir Prescribing Patterns During the COVID-19 Pandemic. (Pubmed Central) -  Aug 3, 2024   
    However, nirmatrelvir/ritonavir prescribing to children with chronic conditions remains infrequent. Pediatric data concerning nirmatrelvir/ritonavir safety and effectiveness in preventing severe disease and hospitalization are critical optimizing clinical decision-making and use among children.
  • ||||||||||  Paxlovid (nirmatrelvir/ritonavir) / Pfizer
    NIRMATRELVIR/RITONAVIR-INDUCED SIADH: A CASE SERIES (Convention Center Exhibit Hall: Poster Area 2) -  Jul 31, 2024 - Abstract #CHEST2024CHEST_5298;    
    Nirmatrelvir/ritonavir-induced SIADH is an underappreciated cause of severe hyponatremia in the ICU. Clinicians should be aware of this rare complication as use of this important medication becomes more routine.
  • ||||||||||  Olumiant (baricitinib) / Eli Lilly, Paxlovid (nirmatrelvir/ritonavir) / Pfizer
    SPONTANEOUS PNEUMOTHORAX: AN EMERGING COMPLICATION OF CORONAVIRUS DISEASE 19 (COVID-19) (Convention Center Exhibit Hall: Poster Area 2) -  Jul 31, 2024 - Abstract #CHEST2024CHEST_5112;    
    While the exact incidence of SP in COVID-19 patients remains to be fully elucidated, healthcare providers should maintain a high index of suspicion for this complication, particularly in patients with worsening respiratory status or refractory hypoxemia. Further research is needed to better understand the pathophysiology and risk factors predisposing COVID-19 patients to SP, which could inform targeted prevention and management strategies.
  • ||||||||||  Paxlovid (nirmatrelvir/ritonavir) / Pfizer
    PULMONARY EMBOLISM LEADING TO SYNCOPE WITH LARYNGEAL TRAUMA AND SUBCUTANEOUS EMPHYSEMA: AN UNCOMMON PRESENTATION OF A COMMON PROBLEM (Convention Center Exhibit Hall: Poster Area 4) -  Jul 31, 2024 - Abstract #CHEST2024CHEST_3029;    
    Although rare, syncope can result in laryngeal trauma, which carries significant morbidity and mortality. Careful and thorough evaluation of the upper airway should be undertaken as part of any trauma evaluation; however, it is of particular importance in the setting of concomitant need for anticoagulation or thrombolytics, as in the setting of acute pulmonary embolism, such as this case.
  • ||||||||||  Cablivi (caplacizumab) / Sanofi
    CAPLACIZUMAB: THE NEW KID ON THE BLOCK AGAINST VWF (Convention Center Exhibit Hall: Poster Area 2) -  Jul 31, 2024 - Abstract #CHEST2024CHEST_2672;    
    She contracted COVID-19 two weeks prior and completed Paxlovid. Caplacizumab is a novel and effective treatment for acute TTP (including COVID-10-associated TTP) that can offer a plasma-free option for select patients.
  • ||||||||||  Paxlovid (nirmatrelvir/ritonavir) / Pfizer
    A CASE REPORT OF PULMONARY CRYPTOCOCCOSIS IN AN IMMUNOCOMPETENT PATIENT FOLLOWING COVID-19 INFECTION (Convention Center Exhibit Hall: Poster Area 2) -  Jul 31, 2024 - Abstract #CHEST2024CHEST_2542;    
    Clinicians should have a higher index of suspicion in patients with severe COVID-19 infections on high dose corticosteroids. Antifungal prophylaxis in high risk COVID-19 patients on prolonged corticosteroids may become practice in the future.
  • ||||||||||  Paxlovid (nirmatrelvir/ritonavir) / Pfizer
    TUBERCULOSIS-ASSOCIATED IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN A NON-HIV-INFECTED PATIENT (Convention Center Exhibit Hall: Rapid Fire Area 1B) -  Jul 31, 2024 - Abstract #CHEST2024CHEST_1673;    
    Prompt recognition of TB-IRIS in non-HIV infected patients and treatment with corticosteroids may result in improved clinical outcomes. Further research is required to establish disease incidence and optimal treatment strategies.
  • ||||||||||  Ocrevus (ocrelizumab) / Roche
    OCRELIZUMAB-INDUCED DIFFUSE CRYPTOGENIC ORGANIZING PNEUMONIA (Convention Center Exhibit Hall: Poster Area 3) -  Jul 31, 2024 - Abstract #CHEST2024CHEST_1499;    
    Further research is needed to elucidate the mechanisms underlying such adverse events and to guide appropriate patient management strategies. Healthcare providers should remain vigilant for respiratory symptoms in patients receiving ocrelizumab and consider thorough pulmonary evaluation in cases of unexplained respiratory distress.
  • ||||||||||  Paxlovid (nirmatrelvir/ritonavir) / Pfizer
    Journal:  Nirmatrelvir for Adult Outpatients with Covid-19. Reply. (Pubmed Central) -  Jul 31, 2024   
    Healthcare providers should remain vigilant for respiratory symptoms in patients receiving ocrelizumab and consider thorough pulmonary evaluation in cases of unexplained respiratory distress. No abstract available
  • ||||||||||  Evusheld (cilgavimab/tixagevimab) / AstraZeneca, Paxlovid (nirmatrelvir/ritonavir) / Pfizer, Xevudy (sotrovimab) / GSK, National Institutes of Health, Vir Biotech, National Institute of Allergy and Infectious Diseases
    Journal:  Saliva Is a Sensitive and Accessible Sample Both for SARS-CoV-2 Detection and for the Evaluation of Treatment Effectiveness in Follow-Up Studies. (Pubmed Central) -  Jul 31, 2024   
    For this reason, in this study, we used, in parallel, saliva and NPS samples for the detection of SARS-CoV-2 by real-time RT-PCR in patients receiving Tixagevimab/Cilgavimab, Nirmatrelvir/Ritonavir, or Sotrovimab as a treatment against SARS-CoV-2. Our results showed a good correlation between the NPS and saliva samples for each drug; moreover, comparable changes in the cycle threshold (Ct) levels in saliva and NPSs were observed both 7 days and 30 days after treatment, thus confirming that the saliva represents a good matrix for in vivo follow-up studies verifying the effectiveness of treatments against SARS-CoV-2.
  • ||||||||||  Paxlovid (nirmatrelvir/ritonavir) / Pfizer
    Journal:  Nirmatrelvir-Ritonavir for Acute (Pubmed Central) -  Jul 31, 2024   
    No abstract available Similarly, narrowly defined PASC occurred in 5,335 patients (20%) in the NMV-r cohort vs 6,271 patients (23.6%) in the non-NMV-r cohort between 30 and 90
  • ||||||||||  Paxlovid (nirmatrelvir/ritonavir) / Pfizer
    Journal, Real-world evidence, Real-world:  Real-world application of nirmatrelvir/ritonavir in hospitalized COVID-19 patients with onset of symptoms beyond 5 (Pubmed Central) -  Jul 30, 2024   
    Similarly, narrowly defined PASC occurred in 5,335 patients (20%) in the NMV-r cohort vs 6,271 patients (23.6%) in the non-NMV-r cohort between 30 and 90 The application of Nirmatrelvir-ritonavir was associated with a significantly reduced risk of intubation or death in hospitalized COVID-19 patients who experienced symptoms for more than 5
  • ||||||||||  Paxlovid (nirmatrelvir/ritonavir) / Pfizer, Lagevrio (molnupiravir) / Ridgeback Biotherap, Merck (MSD)
    Journal:  The effect of oral antiviral therapy for COVID-19 in managing non-hospitalized patients with lung cancer. (Pubmed Central) -  Jul 28, 2024   
    This study provides an updated progress in SARS-CoV-2 medications and a crucial guide for inventing novel interventions against COVID-19. The study suggests a favorable impact of oral antiviral therapy on the outcomes of COVID-19 in individuals with lung cancer and support the potential utility of oral antiviral agents in improving outcomes in this vulnerable population.
  • ||||||||||  Paxlovid (nirmatrelvir/ritonavir) / Pfizer
    Preclinical, Journal:  In vitro selection and analysis of SARS-CoV-2 nirmatrelvir resistance mutations contributing to clinical virus resistance surveillance. (Pubmed Central) -  Jul 26, 2024   
    SARS-CoV-2 surveillance revealed that in vitro resistance-associated mutations from our studies and those reported in the literature were rarely detected in the Global Initiative on Sharing All Influenza Data database. In the Paxlovid Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients trial, E166V was the only emergent resistance mutation, observed in three Paxlovid-treated patients, none of whom experienced COVID-19-related hospitalization or death.
  • ||||||||||  Paxlovid (nirmatrelvir/ritonavir) / Pfizer
    Journal:  Fixing the Achilles Heel of Pfizer's Paxlovid for COVID-19 Treatment. (Pubmed Central) -  Jul 26, 2024   
    The development of nirmatrelvir and ibuzatrelvir dramatically highlights the power of appropriately resourced modern medicinal chemistry to very rapidly enable the development of breakthrough medicines. Consideration of how analogous approaches can be used to develop similarly breakthrough medicines for infectious diseases such as tuberculosis and malaria is worthwhile.
  • ||||||||||  Paxlovid (nirmatrelvir/ritonavir) / Pfizer
    Clinical, Journal:  Telemedicine for Prescribing Nirmatrelvir/Ritonavir: Safety, Logistics, and Challenges. (Pubmed Central) -  Jul 22, 2024   
    This study describes our experience prescribing nirmatrelvir/ritonavir within a small interdisciplinary team with a specific focus on management of drug-drug interactions. Ascertaining and communicating modifications of concomitant medications is a key safety element.
  • ||||||||||  Paxlovid (nirmatrelvir/ritonavir) / Pfizer
    Journal:  Nirmatrelvir has detrimental effects on sperm function by altering the PI3K/PDK1/AKT signaling pathway. (Pubmed Central) -  Jul 21, 2024   
    Combining these findings, it is suggested that NMV has detrimental effects on sperm function by inducing abnormal changes in the PI3K/PDK1/AKT signaling pathway, resulting in PKA deactivation. Therefore, there is a need to pay particular attention to its male reproductive toxicity when NMV is administered.
  • ||||||||||  Paxlovid (nirmatrelvir/ritonavir) / Pfizer
    Journal:  A Rare Cause of Acute Liver Failure. (Pubmed Central) -  Jul 21, 2024   
    Therefore, there is a need to pay particular attention to its male reproductive toxicity when NMV is administered. No abstract available
  • ||||||||||  Paxlovid (nirmatrelvir/ritonavir) / Pfizer
    Journal:  Is Paxlovid Still Worth It? (Pubmed Central) -  Jul 19, 2024   
    No abstract available No abstract available
  • ||||||||||  Paxlovid (nirmatrelvir/ritonavir) / Pfizer
    Journal:  Combined protection of vaccination and nirmatrelvir-ritonavir against hospitalization in adults with COVID-19. (Pubmed Central) -  Jul 19, 2024   
    Among U.S. adults at risk for severe COVID-19 in Epic Cosmos, the lowest rate of hospitalization was among those receiving three or more mRNA vaccine doses and nirmatrelvir-ritonavir (aHR 0.22, 95%CI: 0.19-0.24). Adults who are at high-risk of severe COVID-19 disease, including vaccinated persons, should be considered for antiviral treatment.
  • ||||||||||  Paxlovid (nirmatrelvir/ritonavir) / Pfizer
    Review, Journal:  Top 20 Research Studies of 2023 for Primary Care Physicians. (Pubmed Central) -  Jul 19, 2024   
    An observational study of people with acute COVID-19 in the Omicron phase showed that nirmatrelvir/ritonavir was effective in reducing hospitalizations and death...Dextromethorphan, honey, and inhaled ipratropium do not appear to be effective for acute cough...Mindfulness-based stress reduction is not inferior to escitalopram in adults with anxiety disorders...People labeled as having a penicillin allergy can complete an amoxicillin oral provocation challenge in the primary care office and, following a negative result, have this label removed...Nonprescription hearing aids can be effective without a fitting by an audiologist. We wrap this up with the top guidelines of the year as determined by POEM readers.
  • ||||||||||  Paxlovid (nirmatrelvir/ritonavir) / Pfizer
    Resolution of Neuropathic Pain after Anti-Viral Treatment for COVID- A Case Report (Exhibition Hall/Poster Area) -  Jul 18, 2024 - Abstract #IASP2024IASP_800;    
    Anti-retroviral therapy (such as in treating HIV) has been known to causative in sensory neuropathy (4), and the role of oral acyclovir is not thought to be as robust in preventing post-herpetic neuralgia, as per a Cochrane review.(5)We conducted a literature search but could not find any data that Paxlovid was used to treat neuropathic pain. Most systematic reviews, and other studies including some case reports were focused on the treatment of herpes zoster, and herpes zoster ophthalmicus, with anti-viral therapies.
  • ||||||||||  Paxlovid (nirmatrelvir/ritonavir) / Pfizer
    Clinical, Journal:  Oral Nirmatrelvir-Ritonavir as Postexposure Prophylaxis for Covid-19. (Pubmed Central) -  Jul 17, 2024   
    P2/3
    In this placebo-controlled trial, postexposure prophylaxis with nirmatrelvir-ritonavir for 5 or 10 days did not significantly reduce the risk of symptomatic SARS-CoV-2 infection. (Funded by Pfizer; ClinicalTrials.gov number, NCT05047601.).
  • ||||||||||  Review, Journal:  A review on the current approaches and perspectives of Covid-19 treatment. (Pubmed Central) -  Jul 15, 2024   
    The article brief l y describes the current epidemiological situation regarding COVID-19 and the currently used vaccines. Moreover, the paper outlines currently used and researched potential drugs in the pharmacotherapy of this disease.
  • ||||||||||  azvudine (FNC) / Granlen
    Clinical, Observational data, Retrospective data, Review, Journal:  Efficacy and Safety of Azvudine in Patients With COVID-19 in China: A Meta-Analysis of Observational Studies. (Pubmed Central) -  Jul 12, 2024   
    FNC appears to be a safe and potentially effective treatment for COVID-19 in China, but further research with larger, high-quality studies is necessary to confirm these findings. Due to the certainty of the evidence and the specific context of the studies conducted in China, caution should be exercised when considering whether the results are applicable worldwide.